These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice. Juarez JG; Harun N; Thien M; Welschinger R; Baraz R; Pena AD; Pitson SM; Rettig M; DiPersio JF; Bradstock KF; Bendall LJ Blood; 2012 Jan; 119(3):707-16. PubMed ID: 22049516 [TBL] [Abstract][Full Text] [Related]
4. Autophagy is required for stem cell mobilization by G-CSF. Leveque-El Mouttie L; Vu T; Lineburg KE; Kuns RD; Bagger FO; Teal BE; Lor M; Boyle GM; Bruedigam C; Mintern JD; Hill GR; MacDonald KP; Lane SW Blood; 2015 May; 125(19):2933-6. PubMed ID: 25788702 [TBL] [Abstract][Full Text] [Related]
5. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613 [TBL] [Abstract][Full Text] [Related]
6. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma. Steinberg M; Silva M Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493 [TBL] [Abstract][Full Text] [Related]
7. Diabetes Limits Stem Cell Mobilization Following G-CSF but Not Plerixafor. Fadini GP; Fiala M; Cappellari R; Danna M; Park S; Poncina N; Menegazzo L; Albiero M; DiPersio J; Stockerl-Goldstein K; Avogaro A Diabetes; 2015 Aug; 64(8):2969-77. PubMed ID: 25804941 [TBL] [Abstract][Full Text] [Related]
8. Hematopoietic stem cell mobilizing agents G-CSF, cyclophosphamide or AMD3100 have distinct mechanisms of action on bone marrow HSC niches and bone formation. Winkler IG; Pettit AR; Raggatt LJ; Jacobsen RN; Forristal CE; Barbier V; Nowlan B; Cisterne A; Bendall LJ; Sims NA; Lévesque JP Leukemia; 2012 Jul; 26(7):1594-601. PubMed ID: 22266913 [TBL] [Abstract][Full Text] [Related]
9. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor. Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458 [TBL] [Abstract][Full Text] [Related]
10. Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells. Uy GL; Rettig MP; Cashen AF Expert Opin Biol Ther; 2008 Nov; 8(11):1797-804. PubMed ID: 18847313 [TBL] [Abstract][Full Text] [Related]
13. Plerixafor added to G-CSF-supported paclitaxel-ifosfamide-cisplatin salvage chemotherapy enhances mobilization of adequate numbers of hematopoietic stem cells for subsequent autografting in hard-to-mobilize patients with relapsed/refractory germ-cell tumors: a single-center experience. Kosmas C; Athanasopoulos A; Dimitriadis G; Miltiadous C; Zilakos M; Lydakis D; Magiorkinis E; Gekas C; Daladimos T; Mylonakis N; Ziras N Anticancer Drugs; 2014 Aug; 25(7):841-7. PubMed ID: 24625457 [TBL] [Abstract][Full Text] [Related]
14. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers. De Clercq E Pharmacol Ther; 2010 Dec; 128(3):509-18. PubMed ID: 20826182 [TBL] [Abstract][Full Text] [Related]
15. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037 [TBL] [Abstract][Full Text] [Related]
16. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Abhyankar S; DeJarnette S; Aljitawi O; Ganguly S; Merkel D; McGuirk J Bone Marrow Transplant; 2012 Apr; 47(4):483-7. PubMed ID: 21725372 [TBL] [Abstract][Full Text] [Related]